I Buchmann

Summary

Affiliation: University of Heidelberg
Country: Germany

Publications

  1. ncbi Influence of cell proportions and proliferation rates on FDG uptake in squamous-cell esophageal carcinoma: a PET study
    Inga Buchmann
    Klinik und Poliklinik fur Nuklearmedizin, Universitätskliniken Mainz, Mainz, Germany
    Cancer Biother Radiopharm 23:172-80. 2008
  2. ncbi [[18F]-FDG-PET in the diagnostics of gastrointestinal tumors]
    I Buchmann
    Abteilung für Nuklearmedizin, Universitätskliniken Heidelberg, Heidelberg
    Z Gastroenterol 46:367-75. 2008
  3. ncbi Comparison of 99mtechnetium-pertechnetate and 123iodide SPECT with FDG-PET in patients suspicious for breast cancer
    Inga Buchmann
    Department of Nuclear Medicine, University of Heidelberg, Heidelberg, Germany
    Cancer Biother Radiopharm 22:779-89. 2007
  4. ncbi Comparison of 68Ga-DOTATOC PET and 111In-DTPAOC (Octreoscan) SPECT in patients with neuroendocrine tumours
    I Buchmann
    Department of Nuclear Medicine, University Hospital Heidelberg, Im Neuenheimer Feld 400, 69120 Heidelberg, Germany
    Eur J Nucl Med Mol Imaging 34:1617-26. 2007
  5. ncbi FDG-PET in the initial staging of squamous cell oesophageal carcinoma
    I Buchmann
    Nuclear Medicine, University Hospital Heidelberg, Im Neuenheimer Feld 400, 69120 Heidelberg, Germany
    Nuklearmedizin 45:235-41. 2006
  6. ncbi 2-(fluorine-18)fluoro-2-deoxy-D-glucose positron emission tomography in the detection and staging of malignant lymphoma. A bicenter trial
    I Buchmann
    Department of Nuclear Medicine, Ulm University Hospital, Ulm, Germany
    Cancer 91:889-99. 2001
  7. ncbi Different radiosensitivity of smooth muscle cells and endothelial cells in vitro as demonstrated by irradiation from a Re-188 filled balloon catheter
    J Kotzerke
    Department of Nuclear Medicine, University of Ulm, D 89070, Ulm, Germany
    Atherosclerosis 152:35-42. 2000
  8. ncbi Ki-67 immunostaining in pancreatic cancer and chronic active pancreatitis: does in vivo FDG uptake correlate with proliferative activity?
    A C Buck
    Department of Nuclear Medicine, University of Ulm, Ulm, Germany
    J Nucl Med 42:721-5. 2001
  9. ncbi [18F]5-fluoro-2-deoxyuridine-PET for imaging of malignant tumors and for measuring tissue proliferation
    Inga Buchmann
    Abteilung für Nuklearmedizin, Universittskliniken Ulm, Germany
    Cancer Biother Radiopharm 18:327-37. 2003
  10. ncbi [18F]3'-deoxy-3'-fluorothymidine-PET in NHL patients: whole-body biodistribution and imaging of lymphoma manifestations--a pilot study
    Inga Buchmann
    Nuklearmedizin, Universitatskliniken, Ulm, Germany
    Cancer Biother Radiopharm 19:436-42. 2004

Collaborators

Detail Information

Publications16

  1. ncbi Influence of cell proportions and proliferation rates on FDG uptake in squamous-cell esophageal carcinoma: a PET study
    Inga Buchmann
    Klinik und Poliklinik fur Nuklearmedizin, Universitätskliniken Mainz, Mainz, Germany
    Cancer Biother Radiopharm 23:172-80. 2008
    ..We investigated the influence of cell proportions and proliferation activities on tumor maximum standard uptake value (SUV(max)) in patients with squamous-cell esophageal cancer (SCEC)...
  2. ncbi [[18F]-FDG-PET in the diagnostics of gastrointestinal tumors]
    I Buchmann
    Abteilung für Nuklearmedizin, Universitätskliniken Heidelberg, Heidelberg
    Z Gastroenterol 46:367-75. 2008
    ..For gastrointestinal stroma tumours, FDG-PET is useful for the monitoring of therapy and the initial staging. For imaging of hepatocellular carcinoma and carcinoma of the gall bladder, FDG-PET is not sufficient...
  3. ncbi Comparison of 99mtechnetium-pertechnetate and 123iodide SPECT with FDG-PET in patients suspicious for breast cancer
    Inga Buchmann
    Department of Nuclear Medicine, University of Heidelberg, Heidelberg, Germany
    Cancer Biother Radiopharm 22:779-89. 2007
    ....
  4. ncbi Comparison of 68Ga-DOTATOC PET and 111In-DTPAOC (Octreoscan) SPECT in patients with neuroendocrine tumours
    I Buchmann
    Department of Nuclear Medicine, University Hospital Heidelberg, Im Neuenheimer Feld 400, 69120 Heidelberg, Germany
    Eur J Nucl Med Mol Imaging 34:1617-26. 2007
    ..The aim of our study was to compare the value of (68)Ga-DOTATOC PET and (111)In-DTPAOC SPECT (Octreoscan) in the detection of NET manifestations...
  5. ncbi FDG-PET in the initial staging of squamous cell oesophageal carcinoma
    I Buchmann
    Nuclear Medicine, University Hospital Heidelberg, Im Neuenheimer Feld 400, 69120 Heidelberg, Germany
    Nuklearmedizin 45:235-41. 2006
    ..Squamous cell oesophageal carcinoma is the most common carcinoma of the oesophagus worldwide. The tumour stage as most important prognostic factor determines the clinical management...
  6. ncbi 2-(fluorine-18)fluoro-2-deoxy-D-glucose positron emission tomography in the detection and staging of malignant lymphoma. A bicenter trial
    I Buchmann
    Department of Nuclear Medicine, Ulm University Hospital, Ulm, Germany
    Cancer 91:889-99. 2001
    ....
  7. ncbi Different radiosensitivity of smooth muscle cells and endothelial cells in vitro as demonstrated by irradiation from a Re-188 filled balloon catheter
    J Kotzerke
    Department of Nuclear Medicine, University of Ulm, D 89070, Ulm, Germany
    Atherosclerosis 152:35-42. 2000
    ..Within 18 h after irradiation no effect on cytoskeletal components and vWF was documented. This in vitro study demonstrates that irradiation inhibits HCMSMC and HCPSMC at lower dose rates compared to HCAEC...
  8. ncbi Ki-67 immunostaining in pancreatic cancer and chronic active pancreatitis: does in vivo FDG uptake correlate with proliferative activity?
    A C Buck
    Department of Nuclear Medicine, University of Ulm, Ulm, Germany
    J Nucl Med 42:721-5. 2001
    ..The aim of this prospective study was to evaluate a probable correlation between FDG uptake and proliferative activity in benign and malignant pancreatic tumors...
  9. ncbi [18F]5-fluoro-2-deoxyuridine-PET for imaging of malignant tumors and for measuring tissue proliferation
    Inga Buchmann
    Abteilung für Nuklearmedizin, Universittskliniken Ulm, Germany
    Cancer Biother Radiopharm 18:327-37. 2003
    ..FdUrd-PET was less effective than FDG-PET. In this group of patients, it was not useful in measuring tissue proliferation...
  10. ncbi [18F]3'-deoxy-3'-fluorothymidine-PET in NHL patients: whole-body biodistribution and imaging of lymphoma manifestations--a pilot study
    Inga Buchmann
    Nuklearmedizin, Universitatskliniken, Ulm, Germany
    Cancer Biother Radiopharm 19:436-42. 2004
    ..We prospectively evaluated the biodistribution of the PET tracer [18F]3'-deoxy-3'-fluorothymidine (FLT) and its value in detecting manifestations of non-Hodgkin's lymphoma (NHL)...
  11. ncbi FDG PET for imaging pericardial manifestations of Hodgkin lymphoma
    Inga Buchmann
    Abteilung für Nuklearmedizin, Universitätskliniken Ulm, Deutschland
    Clin Nucl Med 28:760-1. 2003
    ..These findings and computed tomographic findings were suspicious for manifestations of Hodgkin lymphoma. The pericardial findings were demonstrated on F-18 fluorodeoxyglucose positron emission tomographic imaging...
  12. ncbi Targeted marrow irradiation with radioactively labeled anti-CD66 monoclonal antibody prior to allogeneic stem cell transplantation for patients with leukemia: results of a phase I-II study
    Thorsten Zenz
    Haematologica 91:285-6. 2006
    ..The intensified conditioning was not associated with increased non-relapse mortality. No reduction in the incidence of relapse was observed in the context of a T-cell depleted graft (4-year overall survival: 29%)...
  13. ncbi Radiolabeled peptides and proteins in cancer therapy
    Carmen Wängler
    Department of Nuclear Medicine, University of Heidelberg, German Cancer Research Centre DKFZ, Germany
    Protein Pept Lett 14:273-9. 2007
    ..Future generations of endoradiopharmaceuticals will address yet unknown targets which might be identified by screening techniques such as ribosome and phage display peptide libraries...
  14. ncbi A comparison of the biodistribution and biokinetics of (99m)Tc-anti-CD66 mAb BW 250/183 and (99m)Tc-anti-CD45 mAb YTH 24.5 with regard to suitability for myeloablative radioimmunotherapy
    Inga Buchmann
    Department of Nuclear Medicine, University Hospital, Ulm, Germany
    Eur J Nucl Med Mol Imaging 30:667-73. 2003
    ..Thus, it appears superior to anti-CD45 mAb YTH 24.5 in selectively increasing the marrow dose and avoiding extramedullary organ toxicity...
  15. ncbi Myeloablative radioimmunotherapy with Re-188-anti-CD66-antibody for conditioning of high-risk leukemia patients prior to stem cell transplantation: biodistribution, biokinetics and immediate toxicities
    Inga Buchmann
    Department of Nuclear Medicine, University Hospital, Ulm, Germany
    Cancer Biother Radiopharm 17:151-63. 2002
    ..We evaluated biodistribution, radiation absorbed organ doses and immediate toxicities of myeloablative radioimmunotherapy with marrow selective 188rhenium (188Re)-labeled anti-CD66 monoclonal antibody (mAb)...
  16. ncbi 188Re or 90Y-labelled anti-CD66 antibody as part of a dose-reduced conditioning regimen for patients with acute leukaemia or myelodysplastic syndrome over the age of 55: results of a phase I-II study
    Mark Ringhoffer
    Department of Internal Medicine III, University of Ulm, Ulm, Germany
    Br J Haematol 130:604-13. 2005
    ..In conclusion, radioimmunotherapy using the anti-CD66 antibody was feasible and safe in our elderly patient group and provided a high marrow dose...